In Vitro Activity of Garenoxacin, a Novel Des-F(6)-quinolone, and Other Orally Administered Antimicrobials Tested Against 50,217 Enterobacteriaceae Collected Worldwide by the SENTRY Antimicrobial Surveillance Program (1999-2003)
In Vitro Activity of Garenoxacin, a Novel Des-F(6)-quinolone, and Other Orally Administered Antimicrobials Tested Against 50,217 Enterobacteriaceae Collected Worldwide by the SENTRY Antimicrobial Surveillance Program (1999-2003), Lead author: Sader HS, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Potency of Garenoxacin, a New Des-F(6)-quinolone, Tested Against Community-acquired Respiratory Tract Infection Pathogens Worldwide (29,837 Strains): Report from the SENTRY Antimicrobial Surveillance Program (1999-2003)
Potency of Garenoxacin, a New Des-F(6)-quinolone, Tested Against Community-acquired Respiratory Tract Infection Pathogens Worldwide (29,837 Strains): Report from the SENTRY Antimicrobial Surveillance Program (1999-2003), Lead author: Jones RN, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Garenoxacin Activity Against Isolates from Patients Hospitalised with Community-acquired Pneumonia (Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis; 3,087 strains): Report from the SENTRY Antimicrobial Surveillance Program (1999-2003)
Garenoxacin Activity Against Isolates from Patients Hospitalised with Community-acquired Pneumonia (Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis; 3,087 strains): Report from the SENTRY Antimicrobial Surveillance Program (1999-2003), Lead author: Jones RN, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Potency and Spectrum of Garenoxacin Tested Against an International Collection of Skin and Soft Tissue Infection Pathogens: Report from the SENTRY Antimicrobial Surveillance Program (1999-2003)
Potency and Spectrum of Garenoxacin Tested Against an International Collection of Skin and Soft Tissue Infection Pathogens: Report from the SENTRY Antimicrobial Surveillance Program (1999-2003), Lead author: Fritsche TR, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Antimicrobial Susceptibility of 5,859 non-Enterobacteriaceae Gram-negative Organisms Other than Pseudomonas aeruginosa Tested Against the Novel Des-F(6)-quinolone, Garenoxaxin (SENTRY Antimicrobial Surveillance Program, 1999-2003)
Antimicrobial Susceptibility of 5,859 non-Enterobacteriaceae Gram-negative Organisms Other than Pseudomonas aeruginosa Tested Against the Novel Des-F(6)-quinolone, Garenoxaxin (SENTRY Antimicrobial Surveillance Program, 1999-2003), Lead author: Sader HS, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Delayed Resistance Selection for Doripenem when Passaging P. aeruginosa Isolates with an Aminoglycoside
Delayed Resistance Selection for Doripenem when Passaging P. aeruginosa Isolates with an Aminoglycoside, Lead author: Biedenbach DJ, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Linezolid Susceptibility Testing Results in Europe: Report from the Worldwide ZAAPS Program (2003)
Linezolid Susceptibility Testing Results in Europe: Report from the Worldwide ZAAPS Program (2003), Lead author: Ross JE, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Significant Increases in the Rate of Fluoroquinolone Resistance Among Gram-negative Bacilli: Six-year (1999-2004) Report from the USA MYSTIC Programme
Significant Increases in the Rate of Fluoroquinolone Resistance Among Gram-negative Bacilli: Six-year (1999-2004) Report from the USA MYSTIC Programme, Lead author: Rhomberg PR, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Accuracy of Three Automated Systems for Susceptibility Testing Selected Gram-negative Bacilli Against Five Broad-spectrum Beta-Lactam Agents
Accuracy of Three Automated Systems for Susceptibility Testing Selected Gram-negative Bacilli Against Five Broad-spectrum Beta-Lactam Agents, Lead author: Sader HS, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Susceptiblity Patterns for Amoxicillin/clavulanate Tests Mimicking Newly Indicated Formulations and Pharmacokinetic Relationships: Does 2:1 Ratio MIC Accurately Reflect Activity Against Beta-Lactamase-Producing H. influenzae and M. catarrhalis
Susceptiblity Patterns for Amoxicillin/clavulanate Tests Mimicking Newly Indicated Formulations and Pharmacokinetic Relationships: Does 2:1 Ratio MIC Accurately Reflect Activity Against Beta-Lactamase-Producing H. influenzae and M. catarrhalis, Lead author: Jones RN, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Diverse Transposons Are Responsible for the Dissemination of Japanese Metallo-beta-lactamase Alleles: Report from the SENTRY Surveillance Programme
Diverse Transposons Are Responsible for the Dissemination of Japanese Metallo-beta-lactamase Alleles: Report from the SENTRY Surveillance Programme, Lead author: Toleman MA, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Genetic Characterisation of the IMP-1 Metallo-beta-lactamase Gene in Enterobacter cloacae Strains from Turkey
Genetic Characterisation of the IMP-1 Metallo-beta-lactamase Gene in Enterobacter cloacae Strains from Turkey, Lead author: Toleman MA, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
In Vitro Activity of Beta-Lactam Antimicrobial Agent Combinations with Aztreonam When Testing Metallo-Beta-Lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp.
In Vitro Activity of Beta-Lactam Antimicrobial Agent Combinations with Aztreonam When Testing Metallo-Beta-Lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp., Lead author: Sader HS, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Transfer and Carriage of Naturally Occurring Pseudomonas aeruginosa Plasmids Harbouring Metallo-beta-lactamase to Enterobacteriaceae Strains
Transfer and Carriage of Naturally Occurring Pseudomonas aeruginosa Plasmids Harbouring Metallo-beta-lactamase to Enterobacteriaceae Strains, Lead author: Castanheira M, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Antimicrobial Activity of Tigecycline Tested Against Bacterial Pathogens from Intensive Care Units
Antimicrobial Activity of Tigecycline Tested Against Bacterial Pathogens from Intensive Care Units, Lead author: Sader HS, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Potency and Spectrum of Tigecycline Tested Against an International Collection (1999-2003) of Bacterial Pathogens Producing Skin and Soft Tissue Infections
Potency and Spectrum of Tigecycline Tested Against an International Collection (1999-2003) of Bacterial Pathogens Producing Skin and Soft Tissue Infections, Lead author: Fritsche TR, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Tigecycline Activity Tested Against 22,950 Bloodstream Infection Isolates Worldwide
Tigecycline Activity Tested Against 22,950 Bloodstream Infection Isolates Worldwide, Lead author: Jones RN, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
In Vitro Activity of New Compounds Tested Against Multi-Drug Resistant S. aureus Isolated in Latin American Medical Centers (LAMCs)
In Vitro Activity of New Compounds Tested Against Multi-Drug Resistant S. aureus Isolated in Latin American Medical Centers (LAMCs), Lead author: Gales AC, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Bactericidal Activity of Vancomycin and Daptomycin Tested Against Heterogeneous and Homogeneous Vancomycin-intermediate S. aureus (hVISA and VISA) Stains
Bactericidal Activity of Vancomycin and Daptomycin Tested Against Heterogeneous and Homogeneous Vancomycin-intermediate S. aureus (hVISA and VISA) Stains, Lead author: Sader HS, presented at 15th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 2 – 5, 2005, Copenhagen, Denmark
Update on the Activity of a Topical Triple Antibiotic Ointment Against Cutaneous Pathogens
Update on the Activity of a Topical Triple Antibiotic Ointment Against Cutaneous Pathogens, Lead author: Jones RN, presented at 63rd annual American Academy of Dermatology Annual Meeting (AAD), February 18 – 22, 2005, New Orleans, Louisiana
Re-evaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for nine beta-lactams: Adjustments of breakpoints for strains producing extended-spectrum beta-lactamases.
Re-evaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for bine beta-lactams: Adjustments of breakpoints for strains producing extended-spectrum beta-lactamases. by Jones, R.N., Craig, W.A., Ambrose, P.G., Dudley, M.N., Pottumarthy, S. published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 235-246
Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998 – 2003).
Potency and spectrum trends for cefepime tested against 65,746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998 – 2003). by Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 265-273
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. by Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN published in Antimicrob. Agents Chemother. 2005; 49 (8): 3501-3512
Emerging metallo-β-lactamase-mediated resistances: A summary report from the worldwide SENTRY Antimicrobial Surveillance Program.
Emerging metallo-b-lactamase-mediated resistances: A summary report from the worldwide SENTRY Antimicrobial Surveillance Program. by Fritsche TR, Sader HS, Toleman MA, Walsh TR and Jones RN published in Clin. Infect. Dis. 2005; 41 (Suppl 4): S276-S278
Trends in linezolid susceptibility patterns: Report from the 2002 – 2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Trends in linezolid susceptibility patterns: Report from the 2002 – 2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. by Anderegg TR, Sader HS, Fritsche TR, Ross JE and Jones RN published in Int. J. Antimicrob. Agents 2005; 26 (1): 13-21
Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. by Jones RN, Fritsche TR and Sader HS published in Diagn. Microbiol. Infect. Dis. 2005; 52 (2): 129-133
Re-evaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms.
Re-evaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms. by Pottumarthy S, Deshpande LM, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (2): 95-99
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi.
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. by Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, Jones RN and Ambrose PG published in Antimicrob. Agents Chemother. 2005; 49 (5): 1775-1781
Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. by Ross JE, Anderegg TR, Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 53-58
Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels.
Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels. by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 67-69
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms.
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. by Jones, R.N., Sader, H.S., Fritsche, T.R. published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 71-74
Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs.
Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. by Stelling JM, Travers K, Jones RN, Turner PJ, O’Brien TF and Levy SB published in Emerg. Infect. Dis. 2005; 11 (6): 873-882
Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multidrug resistant Pseudomonas aeruginosa and Acinetobacter spp.
Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multidrug resistant Pseudomonas aeruginosa and Acinetobacter spp. by Sader, H.S., Jones, R.N. published in Int. J. Antimicrob. Agents. 2005; 25 (5):380-384
Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis.
Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. by Streit, J.M., Steenbergen, J.N., Thorne, G.M., Alder, J., Jones, R.N. published in J. Antimicrob. Chemother. 2005; 55 (4): 574-578
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels.
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels. by Ross JE, Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 51 (3): 219-221
Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002 – 2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002 – 2003): Contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. by Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (4): 282-289
Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan.
Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. by Bell JA, Turnidge JD, Inoue M, Kohno S, Hirakata Y, Ono Y and Jones RN published in J. Antimicrob. Chemother. 2005; 55 (2):276-278
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance.
Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. by Fritsche, TR, Sader, HS, Cleeland, R, Jones, RN published in Antimicrob. Agents Chemother. 2005; 49 (4): 1468-147
Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content.
Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content. by Rhomberg PR, Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (3): 274-276
Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods.
Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. by Jones RN, Anderegg TR and Swenson JM published in J. Clin. Microbiol. 2005; 43 (2): 925-927
Italian metallo-β-Lactamases: A national problem? Report from the SENTRY Antimicrobial Surveillance Programme.
Italian metallo-β-lactamases: A national problem? Report from the SENTRY Antimicrobial Surveillance Programme. by Toleman, M.A., Biedenbach, D., Bennett, D.M.C., Jones, R.N., Walsh, T.R published in J. Antimicrob. Chemother. 2005; 55 (1): 61-70
Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: Report from the SENTRY Antimicrobial Surveillance Program (1997 – 2003).
Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: Report from the SENTRY Antimicrobial Surveillance Program (1997 – 2003). by Pottumarthy, S., Fritsche, T.R., Jones, R.N. published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 147-150
Emerging epidemic of metallo-β-lactamase-mediated resistances.
Emerging epidemic of metallo-β-lactamase-mediated resistances. by Jones, R.N., Biedenbach, D.J., Sader, H.S., Fritsche, T.R., Toleman, M.A., Walsh, T.R. published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 77-84
Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis).
Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). by Jones RN, Sader HS and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 139-141
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American Medical Centres.
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American Medical Centres. by Gales AC, Sader HS, Jones RN published in Clin. Microbiol. Infect. 2005; 11 (2): 95-100
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli.
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. by Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (2):95-109
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. by Bhavnani SM, Hammel JP, Jones RN and Ambrose PG published in Diagn. Microbiol. Infect. Dis. 2005; 51 (1): 31-37
Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997 – 2003).
Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997 – 2003). by DiPersio JR, Deshpande LM, Biedenbach DJ, Toleman MA, Walsh TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 51 (1): 1-7
Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: Validation report from the SENTRY Antimicrobial Surveillance Program.
Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: Validation report from the SENTRY Antimicrobial Surveillance Program. by Pottumarthy S, Fritsche TR, Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 51 (1):57-62
Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections.
Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections. by Sader HS, Biedenbach DJ, Streit JM and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (1): 89-92
